Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | TYK2 | P29597 | 1/20 | 0.46 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | CHUK | O15111 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | BCL6 | P41182 | 2/20 | 0.36 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.35 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | IGF1R | P08069 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16011451 | 0.78 | NUDT1 (0.42) | JAK1TYK2NUDT1CHUKPDPK1 | |
| SCHEMBL24457928 | 0.78 | FGFR1 (0.47) | — | |
| SCHEMBL2745753 | 0.77 | NUDT1 (0.58) | NUDT1PTPN1GRM4BCL6DHFR | |
| SCHEMBL2744648 | 0.75 | BCL6 (0.56) | TYK2NUDT1PTPN1CHUKPDPK1 | |
| SCHEMBL20150368 | 0.75 | NUDT1 (0.40) | NUDT1CHUKBCL6L3MBTL1 | |
| SCHEMBL14994344 | 0.75 | BCL6 (0.56) | NUDT1PTPN1GRM4BCL6LRRK2 | |
| SCHEMBL3139282 | 0.75 | KMT2A (0.49) | PDPK1LRRK2IGF1RL3MBTL1 | |
| SCHEMBL2745948 | 0.73 | DHFR (0.43) | NUDT1DHFR | |
| SCHEMBL31403281 | 0.73 | JAK1 (0.65) | JAK1TYK2GRM4CHUKIGF1R | |
| SCHEMBL13488651 | 0.72 | PDE10A (0.43) | JAK1TYK2NUDT1TBK1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295144-A1 | 2-polysubstituted aromatic ring-pyrimidine derivatives, preparation and medical application thereof | UNIV ZHEJIANG (CN) | 2023-09-21 | — | — | US | claimed |
| US-20210284625-A1 | 2-polysubstituted aromatic ring-pyrimidine derivatives, preparation and medical application thereof | UNIV ZHEJIANG (CN) | 2021-09-16 | — | — | US | claimed |
| EP-3530657-A1 | 2-POLYSUBSTITUTED AROMATIC RING-PYRIMIDINE DERIVATIVE AND PREPARATION AND MEDICAL USE | Zhejiang University (CN) | 2019-08-28 | — | — | EP | claimed |
| EP-4526318-A1 | FLEX-NUCLEOSIDE ANALOGUES, NOVEL THERAPEUTICS AGAINST VIRUSES | University of Maryland, Baltimore County (US) | 2025-03-26 | — | — | EP | disclosed |
| US-20250092080-A1 | FLEX-NUCLEOSIDE ANALOGUES, NOVEL THERAPEUTICS AGAINST VIRUSES | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY | 2025-03-20 | — | — | US | disclosed |
| WO-2023225042-A1 | FLEX-NUCLEOSIDE ANALOGUES, NOVEL THERAPEUTICS AGAINST VIRUSES | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230295144-A1 | 2-polysubstituted aromatic ring-pyrimidine derivatives, preparation and medical application thereof | UNIV ZHEJIANG (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230295144-A1 | 2-polysubstituted aromatic ring-pyrimidine derivatives, preparation and medical application thereof | UNIV ZHEJIANG (CN) | 2023-09-21 | — | — | US | disclosed |
| US-11591325-B2 | 2-polysubstituted aromatic ring-pyrimidine derivatives, preparation and medical application thereof | ZHEJIANG UNIVERSITY (CN) | 2023-02-28 | — | — | US | disclosed |
| US-11591325-B2 | 2-polysubstituted aromatic ring-pyrimidine derivatives, preparation and medical application thereof | ZHEJIANG UNIVERSITY (CN) | 2023-02-28 | — | — | US | disclosed |
| US-20210284625-A1 | 2-polysubstituted aromatic ring-pyrimidine derivatives, preparation and medical application thereof | UNIV ZHEJIANG (CN) | 2021-09-16 | — | — | US | disclosed |
| US-20210284625-A1 | 2-polysubstituted aromatic ring-pyrimidine derivatives, preparation and medical application thereof | UNIV ZHEJIANG (CN) | 2021-09-16 | — | — | US | disclosed |
| EP-3530657-A1 | 2-POLYSUBSTITUTED AROMATIC RING-PYRIMIDINE DERIVATIVE AND PREPARATION AND MEDICAL USE | Zhejiang University (CN) | 2019-08-28 | — | — | EP | disclosed |
| EP-3530657-A1 | 2-POLYSUBSTITUTED AROMATIC RING-PYRIMIDINE DERIVATIVE AND PREPARATION AND MEDICAL USE | Zhejiang University (CN) | 2019-08-28 | — | — | EP | disclosed |
| WO-2018086546-A1 | 2-POLYSUBSTITUTED AROMATIC RING-PYRIMIDINE DERIVATIVE AND PREPARATION AND MEDICAL USE | 浙江大学 | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591325-B2 | 2-polysubstituted aromatic ring-pyrimidine derivatives, preparation and medical application thereof | CHEK1, PLK1, CHEK2 | JAK1 193/4885TYK2 393/4885NUDT1 665/4885 |
| US-20250092080-A1 | FLEX-NUCLEOSIDE ANALOGUES, NOVEL THERAPEUTICS AGAINST VIRUSES | FLNA, PNP, SMCHD1 | JAK1 2837/4885TYK2 470/4885NUDT1 65/4885 |
| US-20230295144-A1 | 2-polysubstituted aromatic ring-pyrimidine derivatives, preparation and medical application thereof | CHEK1, PLK1, CHEK2 | JAK1 193/4885TYK2 393/4885NUDT1 665/4885 |
| US-20210284625-A1 | 2-polysubstituted aromatic ring-pyrimidine derivatives, preparation and medical application thereof | CHEK1, PLK1, CHEK2 | JAK1 193/4885TYK2 393/4885NUDT1 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.